Skip to main content
Premium Trial:

Request an Annual Quote

A special issue for special scientists


You're a busy person. If you're like most of our readers, you probably spend your day scrambling from one meeting to the next, squeezing in experiments and data analysis whenever you can, and after your long, hard day, you finally go home — where you catch up on all of your work e-mail. Sound familiar?

In a field where speed is essential — you need results now, you have to release your data immediately, and there's always a grant application or project presentation looming — it's a rare thing indeed to step back and actually take a moment to appreciate what you and your colleagues have accomplished.

It's that rare moment we offer to you with this issue of Genome Technology, aimed at celebrating the accomplishments of a select group of researchers in this community. In the past several months, readers have asked me for more profiles of up-and-coming scientists. So when we decided to add a bonus tenth issue to our calendar, choosing the theme was simple: who would be the PIs of tomorrow's labs? Who are the rising stars people should be watching right now?

We tapped today's leading PIs to find out, and they had no shortage of names to share with us. The tough part was narrowing the field to the 30 most promising scientists whose profiles you will find on the following pages. Our criteria were simple: they had to be involved in the disciplines that comprise systems biology, and could be no more than five years into their first faculty or equivalent post.

In what has been perhaps the most fun issue we've ever put together, the GT staff got to spend hours talking with these bright researchers not only about what they're doing today, but also about where they see the field going in the years to come (we did get mocked soundly, though, for my own favorite question: “If you were to one day win the Nobel Prize, what accomplishment would you like that to be for?”). What we found was that these scientists are already fluent in some key attributes: if you read the profiles carefully, you'll notice a theme of highly collaborative people who understand the importance of networking and surrounding themselves with other very smart people.

I'd like to thank all of the current lab heads who recommended people for inclusion in this issue, and also GT reporter Matt Dublin for heading up this project. And though we keep our editorial and advertising departments completely separate, I will take a moment to thank our advertisers, whose contributions for this issue have allowed us to give travel stipend honoraria to our profiled investigators.

You'll notice that this issue doesn't look like a typical Genome Technology. With different content comes a different designer, and GenomeWeb's own Elena Coronado has done an outstanding job in giving our bonus issue a very special look. We'll be back to our usual designers, the talented folks at Three Bears, with our next issue.

Finally, for those of you who thought we'd forgotten about the cartoon caption contest we offered earlier this year, don't miss the Blunt End. We held results till now since so many entries were plays on the PI/postdoc dynamic. Check out p. 50 for the winning caption and our honorable mention.


Meredith W. Salisbury

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.